Diverging trends in incidence and mortality, and improved survival of XXXX , in the Netherlands, 1989-2007.

@entity1 @entity5 @entity1892 @entity1893 @entity8450
BACKGROUND: We studied progress in the fight against @entity1893 ( @entity1893 ) in the Netherlands by describing the changes in incidence, treatment, relative survival, and mortality during 1989-2007. @entity1 AND METHODS: We included all adult @entity1 with @entity1893 [i.e. all mature B-, T-, and natural killer (NK) cell @entity5 , with the exception of @entity8450 ], newly diagnosed in the period 1989-2007 and recorded in the Netherlands Cancer Registry (n=55 069). Regular mortality data were derived from Statistics Netherlands. Follow-up was completed up to 1 January 2009. Annual percentages of change in incidence, mortality, and relative survival were calculated. RESULTS: The incidence of indolent B-cell and T- and NK-cell @entity5 rose significantly (estimated annual percentage change=1.2% and 1.3%, respectively); incidence of @entity1892 remained stable. Mortality due to @entity1893 remained stable between 1989 and 2003, and has decreased since 2003. Five-year relative survival rates rose from 67% to 75%, and from 43% to 52%, respectively, for indolent and aggressive mature B-cell @entity5 , but 5-year survival remained stable at 48% for T- and NK-cell @entity5 . CONCLUSIONS: In the Netherlands, incidence of indolent mature B-cell and mature T- and NK-cell @entity5 has increased since 1989 but remained stable for aggressive @entity5 . Survival increased for all mature B-cell @entity5 , preceding a declining mortality and increased prevalence of @entity1893 (17 597 on 1 January 2008).
